Researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products


Industrial Manufacturing  




MarketCap CSL.AX

CSL.AX Australia



CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.


CSL Limited is a global biotechnology company that develops and produces life-saving products used in the treatment of serious medical conditions. The company was founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, and has since grown into a multinational corporation with operations in more than 30 countries.

During World War I, the Australian government established CSL to provide vaccines and other medical products to the military. In the following years, the company expanded its focus to include the production of blood products, such as plasma and clotting factors.

In the 1970s and 1980s, CSL continued to grow and diversify its product line. The company developed a range of new vaccines and began to explore the potential of genetic engineering. In 1987, CSL became a publicly traded company, listing on the Australian Stock Exchange.

During the 1990s, CSL continued to expand its operations globally, opening facilities in the United States, Europe, and Asia. The company also acquired several other biotechnology firms, further diversifying its product line.

In the early 2000s, CSL's focus shifted to specialty biotherapeutics, such as immunoglobulin products and albumin. In 2003, the company acquired Aventis Behring, a major producer of plasma-derived therapies, and began to build out its capabilities in this area.

Over the next decade, CSL continued to expand its global footprint and product portfolio. The company established a major presence in China, opened new manufacturing facilities in the United States and Europe, and developed a range of new therapies for rare and serious medical conditions.

Today, CSL is one of the world's leading biotechnology companies, with more than 27,000 employees and a market capitalization of over $130 billion USD as of March 2023. The company's products are used to treat a range of medical conditions, including hemophilia, immune deficiencies, and neurological disorders, among others.


CSL's mission statement is "to save lives, protect public health and help people with life-threatening medical conditions live full lives." The company aims to achieve this mission by developing and producing innovative, high-quality biopharmaceutical products that address unmet medical needs, while also ensuring the safety and effectiveness of these products for patients. CSL is committed to advancing scientific research and promoting public health through education and advocacy, and to operating with integrity and social responsibility in all aspects of its business.


CSL's vision statement is "to be the global leader in providing innovative, life-saving biotechnology products that make a significant difference to the lives of people with serious medical conditions." The company aims to achieve this vision by focusing on its core strengths in biopharmaceutical research, development, and manufacturing, and by investing in new technologies and capabilities that enable it to stay at the forefront of scientific innovation. CSL is committed to delivering value to its stakeholders, including patients, healthcare providers, employees, and shareholders, and to making a positive impact on society through its work in advancing public health and medical research.

Key Team

Mr. Mark Dehring (Head of Investor Relations)

Mr. Gregory Boss B.S., BS(Hons), J.D. (Exec. VP of Legal & Group Gen. Counsel)

Dr. Karen Etchberger (Exec. VP of Quality & Bus. Services)

Ms. Elizabeth Walker B.A., M.S. (Exec. VP & Chief HR Officer)

Ms. Jemimah Brennan (Head of Communications - Asia Pacific)

Christina Hickie (Sr. Mang. of Communications)

Dr. Wilfried Freudenberg (Department Head of Albumin & Immunoglobulins Production)

Products and Services

CSL's main products and services are focused on biopharmaceuticals, specifically plasma-derived and recombinant therapies that are used to treat a range of serious medical conditions.

One of CSL's primary products is its immunoglobulin (Ig) therapy, which is derived from human plasma and used to treat patients with immune deficiencies, autoimmune disorders, and other conditions. The company also produces a range of clotting factor therapies for patients with hemophilia and other bleeding disorders, as well as albumin therapy for patients with liver disease, burns, and other conditions.

In addition to these core products, CSL also offers a range of other therapies and services, including vaccines for influenza and other infectious diseases, diagnostics for blood and plasma testing, and contract manufacturing services for other biopharmaceutical companies.

CSL's main product and service offerings are focused on meeting the critical medical needs of patients with serious, life-threatening conditions, and the company is committed to advancing scientific research and innovation in the biopharmaceutical industry to continue to develop new and improved therapies.

Leadership team

Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI (Chief Financial Officer)

Dr. Paul F. McKenzie Ph.D. (Chief Operating Officer)


Industrial Manufacturing

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Medical
Number of Employees
20,000 - 50,000
Parkville, New South Wales, Australia
Company Registration
SEC CIK number: 0001274152
Net Income
1B - 20B
Above - 1B
Traded as

Related Companies

Related Companies


Businessabc provides a digital business directory, resources, a marketplace, and a digital blockchain AI certification for businesses, organisations, and professionals.

Follow Us
Produced by
In collaboration with

Copyright 2023 © Businessabc powered by ztudium